Clinical Trial Update: Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin [Phase 3]

View source ↗

Summary

Phase 3 trial comparing rivaroxaban 10 mg once daily with enoxaparin for venous thromboembolism prevention in patients undergoing total hip replacement has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Venous Thromboembolism | Phase 3 | Status: COMPLETED